Global Hepatocellular Carcinoma Drugs Market, By Drug Class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hepatocellular Carcinoma Drugs Market Analysis and Size
The incidence of HCC has evolved considerably during the past few decades and it has become the third leading cause of deaths by cancer globally. The incidence of hepatitis B and hepatitis C chronic liver diseases are growing, the incidence of HCC is prevalent in Asia and Africa, with prevalence rates in men of 35 per 100,000 populations.
Data Bridge Market Research analyses a growth rate in the hepatocellular carcinoma drugs market in the forecast period 2023-2030. The expected CAGR of hepatocellular carcinoma drugs market is tend to be around 8.2% in the mentioned forecast period. The market was valued at USD 1.04 billion in 2022, and it would grow up to USD 1.95 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hepatocellular Carcinoma Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Exelixis, Inc (U.S.), Merck & Co., Inc.(U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), SillaJen, Inc (South Korea), Bayer AG (Germany), Janssen Global Services, LLC (U.S.), Pfizer Inc (U.S.), CELGENE CORPORATION (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc (U.S.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd (Japan), Amgen Inc. (U.S.), Polaris Group (U.S.), Hepion Pharmaceuticals (U.S.), PROVECTUS BIOPHARMACEUTICALS, INC (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hepatocellular carcinoma (HCC) is a major kind of primary liver cancer which arises from the liver cells or hepatocytes. The disease is more prevalent in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of this condition is largely done by several imaging tests such as ultrasound, CT scan, MRI, and liver biopsy. Treatment includes ablation therapy in addition to chemotherapy, radiation therapy, and targeted drug therapy. Mjority of HCC is witnessed in patients with end-stage liver dysfunction.
Hepatocellular Carcinoma Drugs Market Dynamics
Drivers
- Increased Prevalence of Liver Cancer
According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with almost 40,000 Americans diagnosed with liver cancer in 2017 and above 28,000 deaths are reported from the disease. Furthermore, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza as a single agent in the second-line treatment of people suffering from hepatocellular carcinoma.
- Rising Approval of Novel Drugs
There are several clinical advancements combined with the approval of novel drugs by the regulatory agencies for the treatment of hepatocellular carcinoma is enhancing growth of the market. For instance, in April 2017, the U.S. FDA expanded the indications of regorafenib manufactured by Bayer HealthCare Pharmaceuticals Inc., for treatment of patients suffering from hepatocellular carcinoma. The therapy showed major improvement in survival for patients after the failure of standard treatments. Furthermore, in 2017, the U.S. FDA granted accelerated approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for treating hepatocellular carcinoma.
Opportunities
- Increasing Strategic Collaborations Between Organizations
The manufactures are focused on several strategic collaborations to jointly develop and commercialize immunotherapies that are indicated to treat wide range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. made a strategic collaboration agreement to jointly develop and commercialize several immunotherapies as single and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Additionally, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients for treating advanced hepatocellular carcinoma.
- Increasing Prevalence of Hepatocellular Carcinoma
According to the latest research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Furthermore, as per the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) resulted in around 854,000 new cases of liver cancer and 810,000 related deaths in 2015
Restraints/Challenges
- Lack of Drug Approvals
The extreme lack of drug approvals by authorized organizations is hampering the market growth. There are no FDA-approved drugs to treat HCC. Additionally, the limited availability of treatment processes can limit market growth.
- High Cost of Treatment
The rising expenditure associated with the various medications impede the market growth. Additionally, several diagnostic procedures including imaging procedures and liver tissue examination hamper the market's growth.
This hepatocellular carcinoma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatocellular carcinoma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hepatocellular Carcinoma Drugs Market Scope
The hepatocellular carcinoma drugs market is segmented on the basis of drug class, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- PD-1/PD-L1 Inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- Tyrosine Kinase Inhibitors
- Gefitinib
- Erlotinib
- Sorafenib
- Treatment
Treatment Type
- Medication
- Surgery
- Radiotherapy
- Chemotherapy
- Others
Route of Administration
- Oral
- Injectable
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hepatocellular Carcinoma Drugs Market Regional Analysis/Insights
The hepatocellular carcinoma drugs market is analyzed and market size insights and trends are provided by drug class, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the hepatocellular carcinoma drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has witnessed the highest growth for hepatocellular carcinoma drugs market throughout the forecasted period due to the developing number of R&D activities attempted by the companies in the region to create effective treatments for treating of hepatocellular carcinoma.
North America dominates the market due to the presence of key manufacturers of the product and treatment processes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hepatocellular Carcinoma Drugs Market Share Analysis
The hepatocellular carcinoma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hepatocellular carcinoma drugs market.
Key players operating in the hepatocellular carcinoma drugs market include:
- Exelixis, Inc (U.S.)
- Merck & Co., Inc.(U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Lilly (U.S.)
- SillaJen, Inc (South Korea)
- Bayer AG (Germany)
- Janssen Global Services, LLC (U.S.)
- Pfizer Inc (U.S.)
- CELGENE CORPORATION (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Gilead Sciences, Inc (U.S.)
- GSK plc (U.K.)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd (Japan)
- Amgen Inc. (U.S.)
- Polaris Group (U.S.)
- Hepion Pharmaceuticals (U.S.)
- PROVECTUS BIOPHARMACEUTICALS, INC (U.S.)
SKU-